Compare AU

Compare QYLD vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X Nasdaq 100 Covered Call ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Nasdaq 100 Covered Call ETF (QYLD) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

QYLD

DRUG

Popularity

Low

Low

Pearlers invested

13

63

Median incremental investment

$908.00

$967.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,512.50

$1,882.65

Average age group

> 35

26 - 35


Key Summary

QYLD

DRUG

Strategy

QYLD.AX was created on 2023-01-30 by Global X. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8.1m in AUM and 101 holdings. Each Fund aims to provide investors with a return (before fees and other costs) that tracks the performance of the relevant Index.

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Apple Inc (8.77 %)

NVIDIA Corp (8.27 %)

Microsoft Corp (7.71 %)

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Top 3 industries

Information Technology (57.72 %)

Communication Services (18.86 %)

Consumer Discretionary (18.11 %)

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (97.34 %)

Netherlands (0.82 %)

Brazil (0.69 %)

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.6 %

0.57 %


Key Summary

QYLD

DRUG

Issuer

Global X

BetaShares

Tracking index

Cboe Nasdaq 100 Half BuyWrite V2 Index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.6 %

0.57 %

Price

$12.10

$8.15

Size

$9.461 million

$182.401 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

3.66 %

1.90 %

Market

ASX

ASX

First listed date

31/01/2023

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

QYLD

DRUG

Popularity

Low

Low

Pearlers invested

13

63

Median incremental investment

$908.00

$967.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,512.50

$1,882.65

Average age group

> 35

26 - 35


Pros and Cons

QYLD

DRUG

Pros

  • Higher exposure to US market

  • Higher distribution yield

  • Lower management fee

  • Higher price growth

Cons

  • Higher management fee

  • Lower price growth

  • Lower exposure to US market

  • Lower distribution yield

QYLD

DRUG

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home